NL-OMON23939
Recruiting
Not Applicable
Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with oligometastatic disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Erasmus MC
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •1\. Histologically\-proven, resectable adenocarcinoma of the oesophagus or GOJ according to the UICC TNM7 definition (appendix 2\). Tumours of the oesophagus and tumours of which the epicentre is within 5 cm of the GOJ are eligible for inclusion in the trial in the case of adenocarcinomatous histology (Type 1 and Type 2 according to Siewert classification of oesophagogastric adenocarcinoma)
- •2\. Pre\-treatment stage cT1N\+ M1 or cT2\-4a N0/N\+, M1 (In case of stage cT4a, curative resectability has to be explicitly verified by the multidisciplinary tumour board.
- •3\. Oligometastatic disease, which for this study is defined as a maximum of four resectable/treatable metastatic lesions. These four lesions can be present in a maximum of two organs (liver, lung, bones, or adrenal gland). Lymph nodes are not counted as an organ. If metastatic retroperitoneal or supraclavicular lymph nodes are present, this lymph node site counts as one metastatic lesion, and together with the possible metastases in organs cannot exceed the four lesions.
- •4\. Age \= 18 years, \<75 years
- •5\. No prior abdominal, thoracic or cervical radiotherapy overlapping with the CROSS irradiation fields
- •6\. No prior cytotoxic chemotherapy
- •7\. Eastern Cooperative Oncology Group (ECOG) performance status 0\-1 (see Appendix 1\)
- •8\. Adequate cardiac function (cardiac function tests such as echocardiography only necessary in symptomatic patients).
- •9\. Adequate respiratory function (pulmonary function tests only necessary in symptomatic patients)
Exclusion Criteria
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •1\. Patients with tumours of squamous, adenosquamous or other non\-adenocarcinoma histology
- •2\. Patients with advanced irresectable or extensive metastatic oesophageal adenocarcinoma (involving 3 or more organs or more than 4 metastatic lesions)
- •3\. Patients with overt peritoneal dissemination, as detected on PET\-CT or regular CT\-scan. In patients in whom a diagnostic laparoscopy is indicated, tumour\-positive cytology peritoneal fluid is also an exclusion criterion
- •4\. Oesophageal adenocarcinoma evaluated as not curatively\-resectable by the multidisciplinary tumour board , for instance because ingrowth in the trachea
- •5\. Gastric carcinoma (according to UICC TNM7\)
- •6\. Clinically significant (active) cardiac disease (e.g. symptomatic coronary artery disease or myocardial infarction within last 12 months)
- •7\. Clinically significant lung disease (Forced Expiratory Volume in one second (FEV1\) \<1\.5 l)
- •8\. Peripheral neuropathy grade \>1 according to CTCae v4\.0
- •9\. Pregnant and lactating women, or patients of reproductive potential who are not using effective birth control methods. If barrier contraceptives are used, they must be continued by both sexes throughout the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with limited metastatic disease - TNT-OES-1 TRIANL-OMON49762Erasmus MC, Universitair Medisch Centrum Rotterdam20
Active, not recruiting
Phase 1
Chemotherapy followed by chemoradiotherapy for metastatic esophageal cancerPatients (18 – 75 years) who are diagnosed with adenocarcinoma of the oesophagus or GOJ with a resectable primary tumour and de-novo synchronous oligometastatic disease.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-003605-55-NLErasmus MC - University Medical Centre20
Active, not recruiting
Not Applicable
ow-doses radiotherapy and concomitant chemotherapy with pemetrexed in progression desease NSCLC: a dose-descalation phase II study - NDadvanced and/or metastatic NSCLCMedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2008-003690-40-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Not yet recruiting
Phase 3
Chemoradiation and Consolidation Chemotherapy with or without oxaliplatin for distal rectal cancer and Watch and Wait. A multi-center prospective randomized controlled trial. (CCHOWW)RBR-5j3j9z9Hospital Alemão Oswaldo Cruz
Completed
Not Applicable
Alternating Chemotherapy and Radiotherapy in Advanced Laryngeal Cancersaryngeal cancerJPRN-UMIN000007001Aichi Cancer Center26